[Safety of cell culture-based influenza vaccines].
After more than 60 years, the conventional production of influenza vaccines employing fertilized chicken eggs has reached its limits - both in terms of temporal flexibility and vaccine production volume. This situation is compounded by the fact that the present pandemic-driven situation has roughly doubled the overall vaccine demand virtually "overnight". Modem cell culture technology has significant advantages over the conventional method of manufacturing influenza vaccines employing embryonated chicken eggs, and enables manufacturers to respond rapidly to the exploding worldwide seasonal and pandemic-driven need for influenza vaccines. Recent articles in the popular press claiming that cell culture-based influenza vaccines can cause tumours raised uncertainty among physicians and the general population, and also discredit officially accepted assessments and product licensing by the relevant authorities. The present article provides an overview on the cell culture technology and on the safety profile of the cells and of the vaccine product.
Novartis Vaccines and Diagnostics GmbH, Emil-von-Behring-Strasse 76, 35041 Marburg. joe.schmitt@novartis.com
Heinz-Josef
HJ
Schmitt
Jens Peter
JP
Gregersen
Heidi
H
Trusheim
Michael
M
Bröker
D000818:Animals; D002478:Cells, Cultured / Q000276:immunology*; D002642:Chick Embryo; D004196:Disease Outbreaks; D004285:Dogs; D006801:Humans; D007252:Influenza Vaccines / Q000009:adverse effects* / Q000096:biosynthesis* / Q000627:therapeutic use; D007251:Influenza, Human / Q000453:epidemiology / Q000517:prevention & control; D009369:Neoplasms / Q000209:etiology
D007252:Influenza Vaccines